anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Diabetic bladder dysfunction (DBD) is driven in part by inflammation which dysregulates prostaglandin release in the bladder. Precise inflammatory mechanisms responsible for such dysregulation have been elusive. Since prostaglandins impact bladder contractility, elucidating these mechanisms may yield potential therapeutic targets for DBD. In female Type 1 diabetic Akita mice, inflammation mediated by the nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome is responsible for DBD. Here, we utilized female Akita mice crossbred with NLRP3 knock-out mice to determine how NLRP3-driven inflammation impacts prostaglandin release within the bladder and prostaglandin-mediated bladder contractions.
METHODS: Akita mice were crossbred with NLRP3-⁣/- mice to yield four groups of non-diabetics and diabetics with and without the NLRP3 gene. Females were aged to 30 weeks when Akitas typically exhibit DBD. Urothelia and detrusors were stretched ex vivo to release prostaglandins. Prostaglandin E2 (PGE2) and prostaglandin F2α (PGF2α) were quantified using enzyme linked immunosorbent assays (ELISA). In separate samples, ex vivo contractile force to PGE2 and PGF2α +/- the prostaglandin F (FP) receptor antagonist, AL8810, was measured. FP receptor protein expression was determined via western blotting.
RESULTS: Stretch-induced PGE2 release increases in urothelia but decreases in detrusors of diabetics. However, PGE2-mediated bladder contractions are not impacted. Conversely, diabetics show no changes in PGF2α release, but PGF2α-mediated contractions increase significantly. This is likely due to signaling through the FP receptors as FP receptor antagonism prevents this increase and diabetics demonstrate a four-fold increase in FP receptor proteins. Without NLRP3-mediated inflammation, changes in prostaglandin release, contractility, and receptor expression do not occur.
CONCLUSION: NLRP3-dependent inflammation dysregulates prostaglandin release and prostaglandin-mediated bladder contractions in diabetic female Akita mice via FP receptor upregulation.
The present invention provides polynucleotide and amino acid sequences which encode and identify a novel human myeloid terminal differentiation response gene designated MYD118. The present invention also provides for MYD118 antisense molecules. The invention further provides genetically engineered expression vectors and host cells for the production of purified MYD118 polypeptide; antibodies, antagonists and inhibitors of MYD118 polypeptide; and pharmaceutical compositions and methods of treatment based on polynucleotide sequences encoding MYD118 polypeptide. The invention specifically provides for use of the MYD118 polynucleotide sequences as a diagnostic composition for the detection of myeloproliferative diseases and leukemias. The invention also relates to therapeutic methods and compositions based upon the nucleotide and amino acid sequences for MYD118. The invention further provides antibodies which specifically bind to MYD118.
Smartphones have become ubiquitous worldwide, offering significant potential for medical applications by providing healthcare professionals and students with instant access to resources for informed decision-making. However, despite their benefits, overuse of smartphones can lead to physical health issues. Grip strength is recognized as an indicator of overall muscle strength, upper limb function, and various health conditions. Isokinetic testing, a reliable method for measuring muscle performance, has been widely used in studying low back pain but less commonly applied to wrist strength assessment.

Currently, there is a lack of evidence regarding the impact of smartphone overuse on wrist flexor and extensor peak torque, handgrip strength, and function. This research aims to investigate these aspects, providing insights into upper extremity function and potentially aiding ergonomists in addressing musculoskeletal disorders. The study's findings could contribute to the biomechanical evaluation and design of upper extremity tasks, enhance understanding of wrist functioning, and inform ergonomic design considerations. Additionally, the results may help smartphone users adopt better postures and grasping techniques to minimize injuries and maintain hand function, ultimately improving their quality of life.
Although hearing aids (HAs) can improve hearing ability, communication, social and emotional function, and quality of life for people with hearing loss, the adoption rate of HAs is low. A commonly reported barrier to HA uptake is that HAs are not affordable or accessible under the traditional service delivery model, which requires multiple visits to licensed audiologists for identification of hearing loss, customization of the HAs, and continual maintenance and fine-tuning. This hearing healthcare pathway is referred to as the AUD pathway. As an alternative, over-the-counter (OTC) HAs aim to promote earlier HA adoption and improve HA affordability and accessibility. In this healthcare pathway, referred to as the OTC pathway, users self-diagnose hearing loss and fit and program their OTC HAs. Although prior research has supported the feasibility of HA self-fitting and the OTC service-delivery model, little is known about how the OTC pathway impacts users' long-term well-being.

The goal of this study is to characterize the patient journey of individuals who opt for the OTC pathway in comparison to those who select the AUD pathway. The study is a two-site (Iowa City, IA, and Nashville, TN) longitudinal study in which participants choose their preferred healthcare pathways (OTC vs. AUD), and their HA outcomes are tracked for 12 months. Adults with bilateral mild-to-moderate hearing loss are recruited from the community. Upon entering the study, participants choose their preferred pathway and then proceed with the purchase of HAs. In the OTC pathway, participants purchase their chosen OTC HAs directly from OTC companies or retailers. In the AUD pathway, prescription HAs and fitting services are offered by the audiology clinics at the University of Iowa and Vanderbilt University Medical Center. Participants are contacted 1, 6, and 12 months after they begin using their HAs. During each contact, HA outcomes (e.g., HA satisfaction) are measured if participants continue using HAs. If participants have abandoned or under-utilized their HAs, their engagement with post-amplification hearing healthcare behaviors (e.g., seeking HAs again) is assessed. The data from the OTC and AUD pathways are then compared.
The invention relates to the medicines for gynecopathy, in particular to gel for adjusting microecology in vaginas of women, solving the problem that the traditional gynecological lotion kills probiotics while killing pathogens, thus causing vaginal flora imbalance and low immunity and further causing repeated vaginitis. The gel comprises the following components according to mass concentration: 0.5-2% of Carbomer, 0.1-1% of soy peptide, 0.001-0.01% of isoflavone, 0.5-3.5% of carotene and 0.3-3% of tea tree oil. The gel achieves the aim of suppressing pathogens by promoting lactobacillus proliferation. At present, the products in the market aim to kill the bacteria but finally disturb normal flora balance. The gel increases the absolute number of the lactobacillus, a predominant bacterium, simultaneously reduces the pathogens, maintains the balance of microecology in vaginas and improves vaginal cleanliness and the immunity of the vagina mucosa, thus achieving the aims of preventing gynecological vagina inflammation and reducing the reoccurrence rate of gynecological vaginitis. Besides, the formula of the gel is pure vegetable protein, thus being safer than other bacteriostats and bactericides.
Bupropion hydrochloride extended-release tablets (XL) can cause seizure. The risk of seizure is dose-related. The dose should not exceed 300 mg once daily. Increase the dose gradually. Discontinue bupropion hydrochloride extended-release tablets (XL) and do not restart treatment if the patient experiences a seizure.

The risk of seizures is also related to patient factors, clinical situations, and concomitant medications that lower the seizure threshold. Consider these risks before initiating treatment with bupropion hydrochloride. Bupropion hydrochloride is contraindicated in patients with a seizure disorder or conditions that increase the risk of seizure (e.g., severe head injury, arteriovenous malformation, CNS tumor or CNS infection, severe stroke, anorexia nervosa or bulimia, or abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Contraindications (4)]. The following conditions can also increase the risk of seizure: concomitant use of other medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids), metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia), or use of illicit drugs (e.g., cocaine) or abuse or misuse of prescription drugs such as CNS stimulants. Additional predisposing conditions include diabetes mellitus treated with oral hypoglycemic drugs or insulin, use of anorectic drugs, excessive use of alcohol, benzodiazepines, sedative/hypnotics, or opiates.

Incidence of Seizure with Bupropion Hydrochloride Use

The incidence of seizure with bupropion hydrochloride extended-release tablets (XL) has not been formally evaluated in clinical trials. In studies using bupropion HCl sustained-release up to 300 mg per day the incidence of seizure was approximately 0.1% (1/1,000 patients). In a large prospective, follow-up study, the seizure incidence was approximately 0.4% (13/3,200) with bupropion HCl immediate-release in the range of 300 mg to 450 mg per day.

Additional data accumulated for bupropion immediate-release suggests that the estimated seizure incidence increases almost tenfold between 450 and 600 mg/day. The risk of seizure can be reduced if the bupropion hydrochloride extended-release tablets (XL) dose does not exceed 450 mg once daily and the titration rate is gradual.
Two hundred mL of the bacterial suspension (microbiota transplantation) will be instilled into the small intestine via a catheter introduced through the biopsy channel of the endoscope and the flushed with 25 mL of sterile pre-reduced 0.9% saline. After removal of the endoscope, after recovery, patients will be allowed to resume a normal diet and physical activities.
Compositions, formulations, methods, and systems for treating thyroid eye disease and related conditions (e.g., Grave's Ophthalmopathy). The methods described herein include administering, to a patient in need, systemic or local beta adrenergic agonists (e.g., as an extended release crystalline microparticle suspension). The methods can further include administering a compound for reducing beta adrenergic receptor desensitization (e.g., a corticosteroid) prior to administering or coadministered with the beta adrenergic agonist. The methods can also include locally administering to the eye an immunosuppressant agent (e.g., rapamycin) prior to administering a beta adrenergic agonist. The compositions described herein include ophthalmic pharmaceutical formulations of beta adrenergic agonists in the form of extended release crystalline microparticle suspensions or mixtures of the crystalline microparticle suspensions with beta adrenergic agonist solutions. The compositions also include ophthalmic formulations of a compound for reducing beta adrenergic receptor desensitization in the form of extended release crystalline microparticle suspensions.
PURPOSE:To obtain the titled agent useful as an antitumor agent, by culturing a specific microbial strain belonging to Streptomyces genus and using the obtained substance or its derivative as an active component. CONSTITUTION:The objective agent contains 4181-2 substance of formula (R1 and R2 are H, alkyl or acyl) and its derivative as an active component. The compound of formula can be separated from microbial cell or culture liquid produced by culturing a 4181-strain belonging to Streptomyces genus (FERM P-1010) under proper condition. The pH of the culture medium is preferably adjusted to slightly acidic or nearly neutral state. The culture temperature is usually 20-37 deg.C, preferably about 27-30 deg.C. The 4181-2 substance is produced and accumulated within about 2-5 days in the case of liquid culture. The 4181-2 substance exhibits excellent antitumor effect and a significant life- prolonging effect was found against mouse leukemia.
Patients who will be randomized to high flow nasal cannula therapy. High flow nasal oxygen cannula will be applied at a flow of 20 L/min at FiO2 of 0.4 at a temperature of 36oC.
PURPOSE: The exact link between cognitive impairment (CI) and chronic obstructive pulmonary disease (COPD) is still limited. Thus, we aim to find the relationship and interaction of quantitative CT (QCT), lung function, HIF-1α, and clinical factors with the development of CI among COPD patients.
PATIENTS AND METHODS: A cross-sectional multicentre study was conducted from January 2022 to December 2023. We collected clinical data, spirometry, CT images, and venous blood samples from 114 COPD participants. Cognitive impairment assessment using the Montreal Cognitive Assessment Indonesian version (MoCA-Ina) with a cutoff value 26. The QCT analysis consists of lung density, airway wall thickness, pulmonary artery-to-aorta ratio (PA:A), and pectoralis muscles using 3D Slicer software. Serum HIF-1α analysis was performed using ELISA.
RESULTS: We found significant differences between %LAA-950, age, COPD duration, BMI, FEV1 pp, and FEV1/FVC among GOLD grades I-IV. Only education duration was found to correlate with CI (r = 0.40; p < 0.001). We found no significant difference in HIF-1α among GOLD grades (p = 0.149) and no correlation between HIF-1α and CI (p = 0.105). From multiple linear regression, we observed that the MoCA-Ina score was influenced mainly by %LAA-950 (p = 0.02) and education duration (p = 0.01). The path analysis model showed both %LAA and education duration directly and indirectly through FEV1 pp contributing to CI.
CONCLUSION: We conclude that the utilization of QCT parameters is beneficial as it can identify abnormalities and contribute to the development of CI, indicating its potential utility in clinical decision-making. The MoCA-Ina score in COPD is mainly affected by %LAA-950 and education duration. Contrary to expectations, this study concludes that HIF-1α does not affect CI among COPD patients.
PURPOSE: A solid shampoo composition containing natural ingredient is provided to reduce stimulation on scalp, prevent depilation, and improve moisture maintenance and nutrient feeding effect. CONSTITUTION: A solid shampoo composition containing natural ingredient comprises 25-35 parts by weight of fatty acid, 35-40 parts by weight of moisturizer, 15-20 parts by weight of dispersing agent, 10-15 parts by weight of acidity control agent, 12-15 parts by weight of caustic soda, and 50-60 parts by weight of additives. The fatty acid comprises 20 parts by weight of stearic acid, 10 parts by weight of lauric acid, 10 parts by weight of myristic acid, and 10 parts by weight of palmitic acid. The moisturizer includes glycerin and sorbitol. The dispersing agent includes ethanol. The acidity control agent includes triethanolamine. The caustic soda comprises 100 parts by weight of herbal medicine squeezed water and 50 parts by weight of caustic soda powder. The herbal medicine material comprises Polygoni multiflori Radix, Acori graminei Rhizoma, Oriental arbor vitae, Ecliptae Herba, black soybean, Menthae Herba, and Chrysanthemi Flos.
OBJECTIVES: Feline nasopharyngeal stenosis (NPS) is an uncommon disease in cats. The aim of this study was to compare the outcome with endoscopic and surgical treatments.
METHODS: In this retrospective study, medical records were searched for cases of NPS and cases were divided into three groups: endoscopic treatment (balloon dilation); surgical treatment; or no treatment. Data are presented as median and range. Success rates and length of post-procedure corticosteroid treatment were compared between the two treated groups.
RESULTS: A total of 21 cases were included: 10 males and 11 females (median age 6.7 years, range 0.5-14.4). Clinical signs at the time of initial presentation included permanent stertor (19/21), increased respiratory efforts (9/21), nasal discharge (9/21) and cough/reverse sneezing (6/21) with a duration in the range of 3-60 months. Diagnosis was based on endoscopy (21 cases) and CT (19 cases). In total, 12 cases were treated with endoscopic balloon dilation; 11 cases demonstrated a complete resolution of clinical signs (two cats had two dilations) and one case showed incomplete improvement after one balloon dilation but was successfully treated surgically. Eight cats were treated surgically (including one cat that was originally treated with balloon dilation), including seven cases with complete resolution of clinical signs and one case with a rostral NPS that failed to respond. Two cats were not treated and are still alive more than 3 years after diagnosis. The success rate was not different between the endoscopic (11/12) and surgically treated cases (7/8) (P = 0.85). The outcome was considered excellent in most of the cases as 18/23 procedures were successful, at least until the medium term, and 15/18 treated cats had no clinical signs of minimal stertor at follow-up.
CONCLUSIONS AND RELEVANCE: This preliminary study suggests that minimally invasive endoscopic treatment of NPS has a high success rate and should be attempted in all cases with perforate stenotic membranes. When not achievable, extended palatoplasty can be recommended as a good alternative.
The intervention is K1-70 intramuscular or K1-70 intravenous. This is a single, ascending, intramuscular or intravenous dose, sequential group study.
A transdermal double-layer microneedle based on hydrogen producing probiotics and its preparation method and application thereof are provided. The transdermal double-layer microneedle consists of a needle body and a backing layer. The raw material of the needle body includes hyaluronic acid and hyaluronidase. The raw material of the backing layer includes methacrylate anhydride gelatin and silk fibroin protein. The hydrogen producing bacteria are loaded in the microneedles, and the pore size of the matrix material is lower than the diameter of the probiotics, which will not lead to the leakage of bacteria and has high safety. Treatment of inflammatory skin diseases by gas has low side effects. The needle tip is loaded with hyaluronidase to increase the tissue space and improve the effect of gas treatment. It is expected to be used in psoriasis and other inflammatory skin diseases.
OBJECTIVE: To elucidate the mechanism of Pentraxin 3 (PTX3) in the pathogenesis of psoriasiform dermatitis using Ptx3-knockout (Ptx3-KO) background mice.
METHODS: An Imiquimod (IMQ)-induced murine psoriatic model was created using Ptx3-KO (Ptx3-/-) and wild-type (Ptx3+/+) mice. Skin lesion severity and expression of inflammatory mediators (IL-6 and TNFα) were assessed using PASI score and ELISA, respectively. Cutaneous tissues from the two mice groups were subjected to histological analyses, including HE staining, Masson staining, and Immunohistochemistry (IHC). The PTX3, iNOS, COX2, and Arg1 expressions were quantified and compared between the two groups. We used RNA-seq to clarify the underlying mechanisms of the disease. Flow cytometry was used to analyze systemic Th17 cell differentiation and macrophage polarization.
RESULT: The psoriatic region exhibited a higher PTX3 expression than the normal cutaneous area. Moreover, PTX3 was upregulated in HaCaT cells post-TNFα stimulation. Upon IMQ stimulation, Ptx3-/- mice displayed a lower degree of the psoriasiform dermatitis phenotype compared to Ptx3+/+ mice. Consistent with the RNA-seq results, further experiments confirmed that compared to the wild-type group, the PTX3-KO group exhibited a generally lower IL-6, TNFα, iNOS, and COX2 expression and a contrasting trend in macrophage polarization. However, no significant difference in Th17 cell activation was observed between the two groups.
CONCLUSIONS: This study revealed that PTX3 was upregulated in psoriatic skin tissues and TNFα-stimulated HaCaT cells. We also discovered that PTX3 deficiency in mice ameliorated the psoriasiform dermatitis phenotype upon IMQ stimulation. Mechanistically, PTX3 exacerbates psoriasiform dermatitis by regulating macrophage polarization rather than Th17 cell differentiation.
The invention discloses the use of Hulisan Jiaonang in the preparation of a medicine for treating scabies. Hulisan Jiaonang is the exclusive product of Yunnan Yunhe Pharmaceutical Industry Co, Ltd. The formula of Hulisan Jiaonang comprises 700 grams of processed kusnezoff monkshood root, 100 grams of pseudo-ginseng root, 50 grams of root of wallich swallowwort and 150 grams of crepis crocea. The preparation method of Hulisan Jiaonang comprises: grinding the four medicines into fine powder, sieving, uniformly mixing, and filling into capsules. 0.3 gram of Hulisan Jiaonang is taken each time, and the Hulisan Jiaonang is taken 1 to 2 times a day. Hulisan Jiaonang is for external administration, namely the content is to be spread on affected parts. Hulisan Jiaonang now is found to be capable of treating scabies through external administration.
Participants will be treated only by modulation of their lifestyle. Administration of tinnitus intensity on a scale of 0-10 and questionary.
The invention discloses a traditional Chinese medicine gel preparation for treating chronic cervicitis. The traditional Chinese medicine gel preparation is prepared from, by weight, 15-20 parts of cordate houttuynia, 10-15 parts of radix bupleuri, 5-10 parts of morinda officinalis, 5-10 parts of cacumen biotae, 5-10 parts of lophatherum gracile, 4-8 parts of polygonum cuspidatum, 0.05-0.1 part of alums, 1.5-2.5 parts of substrate gel, 40-50 parts of humectants, 0.3-0.6 part of preservative and 300-400 parts of water. One or several of Carbomer 940, carboxymethyl cellulose sodium, chitosan, agar, gelatin and starch is or are selected as the substrate gel. The humectants are glycerinum or propylene glycol. The preservative is sodium benzoate or benzoic acid or benzalkonium bromide or chlorhexidine acetat or sorbic acid and sorbate or ethylparaben. The invention further discloses a preparing method of the traditional Chinese medicine gel preparation. The traditional Chinese medicine gel preparation is good in curative effect, fast in effect, free of toxic and side effects, easy to prepare, convenient to take, simple in material drawing and low in cost.
Successfully screened participants in Part A will be randomly assigned to Experimental group versus Control group at a ratio of 2:1. Participants in Experimental group will receive KN057 prophylaxis through the main trial (26 weeks) and extension period (26 weeks) for total of approximately 1 year.
Focal therapy is increasingly popular due to its minimal side effect profile. Furthermore, HIFU has demonstrated favorable oncologic outcomes in well selected patients, including those with intermediate and high risk disease. In patients with radiorecurrent prostate cancer there remains a paucity of data on the value of focal therapy. Review of focal HIFU rather than whole gland HIFU is based on largely retrospective data and in an era where mpMRI and PSMA PET was not yet widely implemented thus not reflecting the current patient population seeking this care. In fact, and to the investigators' knowledge, only one study has prospectively evaluated focal HIFU therapy in radiorecurrent prostate cancer. Further evaluation into the value of focal HIFU in select men with localized radiorecurrent clinically significant prostate cancer is needed (clinically significant prostate cancer defined as GG2 or above. GG1 prostate cancer will not be considered clinically significant prostate cancer), both in terms of oncologic and functional outcomes as this patient population is increasing.